ANI PHARMACEUTICALS INCANIPEarnings & Financial Report
Nasdaq · Health Care · Pharmaceutical Preparations
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 12.40% | 2.5M | — | 2024-01-23 |
| Meridian Venture Partners II GP, L.P. | 6.70% | 1.4M | ▼ -1.40pp | 2024-03-14 |
| The Vanguard Group | 6.31% | 1.3M | — | 2024-02-13 |
| Esjay LLC | 4.60% | 932.6K | ▼ -0.20pp | 2024-01-17 |
| Rubric Capital Management LP | 0.27% | 56.7K | ▼ -5.24pp | 2024-11-13 |
Insider Transactions
Net 90d: −$4.05M · buys $0 / sells $4.05MRange:
Action:
Role:
| Insider | Role | Action | ||||
|---|---|---|---|---|---|---|
| 2026-04-13 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | Sell (open market) | 500 | $77.95 | $39.0K |
| 2026-03-13 | Christopher Mutz | HEAD OF RARE DISEASE | Sell (open market) | 3.2K | $71.64 | $226.5K |
| 2026-03-13 | Meredith Cook | SR. VP, GENERAL COUNSEL & SEC. | Sell (open market) | 500 | $72.62 | $36.3K |
| 2026-03-11 | Rowland Thomas Andrew | SVP, HEAD - ESTABLISHED BRANDS | Sell (open market) | 4.8K | $74.91 | $357.5K |
| 2026-03-09 | Christopher Mutz | HEAD OF RARE DISEASE | Sell (open market) | 3.6K | $74.18 | $267.2K |
| 2026-03-09 | Krista Davis | SVP, CHIEF HR OFFICER | Sell (open market) | 5.1K | $74.13 | $377.1K |
| 2026-03-06 | Christopher Mutz | HEAD OF RARE DISEASE | Sell (open market) | 2.1K | $74.22 | $157.4K |
| 2026-03-06 | Krista Davis | SVP, CHIEF HR OFFICER | Sell (open market) | 1.5K | $75.00 | $111.4K |
| 2026-03-05 | CAREY STEPHEN P. | SVP & CFO | Option exercise | 3.3K | $49.51 | $164.0K |
| 2026-03-05 | CAREY STEPHEN P. | SVP & CFO | Sell (open market) | 3.3K | $75.42 | $249.8K |
1–10 of 28
Page 1 / 3